Anavex Selects The Alfred Hospital in Melbourne, Australia as Lead Site for Phase 2a Alzheimer’s Clinical Trial

New York, NY – August 26, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, has selected The Alfred Hospital in Melbourne, Australia as the lead site…

Anavex Reports That Antidepressant Fluvoxamine Reduces Stress Through Sigma-1 Receptor

New York, NY – August 19, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, announced today new data published in the current issue of Cell Death…

Anavex Appoints Experienced Pharma Executive as Vice President of Clinical Operations

New York, NY – August 7, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, announced today the appointment of Tasos Zografidis, PhD as Vice President, Clinical…